Acknowledgements
RECRUITMENT
The authors wish to thank past and future patients who agreed to participate in the HOPExt trial. The authors also thank the Direction pour la Recherche en Santé of the Hospices Civils de Lyon for sponsoring the study and for their help in conducting and monitoring the trial as well as Corinne Brochier and Nina Pronina of the Clinical research Center of the Croix Rousse hospital (Hospices Civils de Lyon) for helping in obtaining study funding and for patient recruitment and follow-up. The authors are also grateful to Laure Lalande, pharmacist, who coordinated study drug supply to all centers.